- Home
- VKTX vs ALKS Comparison
VKTX vs ALKS Comparison
Compare VKTX & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- ALKS
- Stock Information
- Founded
- VKTX 2012
- ALKS 1987
- Country
- VKTX United States
- ALKS Ireland
- Employees
- VKTX N/A
- ALKS N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- VKTX Health Care
- ALKS Health Care
- Exchange
- VKTX Nasdaq
- ALKS Nasdaq
- Market Cap
- VKTX 4.7B
- ALKS 4.7B
- IPO Year
- VKTX 2015
- ALKS 1991
- Fundamental
- Price
- VKTX $32.87
- ALKS $30.10
- Analyst Decision
- VKTX Strong Buy
- ALKS Buy
- Analyst Count
- VKTX 12
- ALKS 11
- Target Price
- VKTX $106.75
- ALKS $36.00
- AVG Volume (30 Days)
- VKTX 3.5M
- ALKS 1.3M
- Earning Date
- VKTX 02-05-2025
- ALKS 02-13-2025
- Dividend Yield
- VKTX N/A
- ALKS N/A
- EPS Growth
- VKTX N/A
- ALKS 55.25
- EPS
- VKTX N/A
- ALKS 1.97
- Revenue
- VKTX N/A
- ALKS $1,505,121,000.00
- Revenue This Year
- VKTX N/A
- ALKS N/A
- Revenue Next Year
- VKTX N/A
- ALKS N/A
- P/E Ratio
- VKTX N/A
- ALKS $15.28
- Revenue Growth
- VKTX N/A
- ALKS N/A
- 52 Week Low
- VKTX $20.92
- ALKS $22.90
- 52 Week High
- VKTX $99.41
- ALKS $32.88
- Technical
- Relative Strength Index (RSI)
- VKTX 26.61
- ALKS 59.48
- Support Level
- VKTX $32.51
- ALKS $28.28
- Resistance Level
- VKTX $43.55
- ALKS $29.36
- Average True Range (ATR)
- VKTX 2.15
- ALKS 0.69
- MACD
- VKTX -0.41
- ALKS 0.12
- Stochastic Oscillator
- VKTX 17.78
- ALKS 97.96
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.